What is the recommended treatment regimen for acquired hyperpigmentation?

Treatment of Acquired Hyperpigmentation

For acquired hyperpigmentation (melasma, post-inflammatory hyperpigmentation), start with topical hydroquinone combined with tretinoin and sunscreen as first-line therapy, with autologous platelet concentrates (APCs) or tranexamic acid as effective adjunctive options based on the most recent guideline evidence.

First-Line Topical Therapy

The foundation of hyperpigmentation treatment involves a multimodal topical approach targeting different mechanisms:

Core Topical Agents

• Hydroquinone remains the gold standard for epidermal hyperpigmentation, functioning as a tyrosinase inhibitor 1, 2
• Tretinoin (topical retinoid) promotes keratinocyte turnover and enhances penetration of other agents 1
• Corticosteroids reduce inflammation and can be combined in triple therapy formulations 1
• Broad-spectrum sunscreen (SPF 30+) is mandatory to prevent UV-induced melanogenesis 1, 3

Important caveat: Hydroquinone has been banned from over-the-counter products in Europe due to concerns about irritation, contact dermatitis, ochronosis, and potential carcinogenicity, though this remains debated 4. Consider alternative agents in regions with restrictions.

Alternative Topical Agents

When hydroquinone is contraindicated or unavailable:

• Azelaic acid: Tyrosinase inhibitor with anti-inflammatory properties 5, 6
• Cysteamine 5% cream: Demonstrated 30-40% improvement in pigmentation indices within 16 weeks 7
• Topical tranexamic acid: Shows 30-40% improvement when used in combination formulations 1, 7
• Kojic acid and glycolic acid: Second-line options for tyrosinase inhibition 6

Emerging Injectable Therapies (2025 Evidence)

Autologous platelet concentrates (APCs) represent a significant advancement for melasma and hyperpigmentation based on the most recent guideline 1:

APC Protocol

• Three treatment sessions spaced minimum 21 days apart
• Maintenance treatment every 6 months thereafter
• Demonstrated significant reduction in modified Melasma Area and Severity Index (mMASI) scores across multiple RCTs 1
• Must be combined with effective home care routine and sun protection 1
• Intradermal PRP injections showed higher efficacy than tranexamic acid in comparative studies 1

Critical point: Melasma should be managed as a chronic condition requiring regular follow-ups 1.

Systemic Therapy

Oral Tranexamic Acid

• Emerging as effective systemic option for melasma 6, 7
• Provides 30-40% improvement in pigmentation with favorable safety profile 7

Oral Isotretinoin (Novel Application)

Recent 2025 multi-institutional data on acquired dermal macular hyperpigmentation (ADMH) shows:

• 20 mg daily for average 8 months improved 90.4% of patients 8
• Better response in patients with disease duration <5 years, localized lesions, and Fitzpatrick skin types III-VI 8
• Particularly effective for Riehl's melanosis (63% marked improvement) 8

Procedural Interventions

Chemical Peels

• Single superficial chemical peel followed by 12-week topical maintenance (hydroquinone 4%, tri-retinol, SPF 30+) demonstrated 50-75% improvement in facial hyperpigmentation 9
• Cost-effective alternative to multiple in-office procedures 9
• Use cautiously in darker skin types due to risk of post-inflammatory hyperpigmentation 5, 7

Laser Therapy

• High-fluence laser most appropriate for hyperpigmentation due to increased melanocytes 5
• Laser toning alternative for epidermal hyperpigmentation 5
• Exercise extreme caution in skin of color - risk of paradoxical hyperpigmentation 7

Treatment Algorithm by Severity

Mild-to-Moderate Hyperpigmentation

1. Start: Triple therapy (hydroquinone + tretinoin + corticosteroid) + SPF 30+ sunscreen
2. Add at 4-8 weeks if inadequate response: Single chemical peel, then continue topical maintenance
3. Consider at 12 weeks: APC therapy (3 sessions over 6 weeks) if persistent

Moderate-to-Severe or Refractory Cases

1. Start: Triple therapy + SPF 30+ sunscreen
2. Add immediately: APC therapy (3 sessions, 21-day intervals)
3. Consider: Oral tranexamic acid or oral isotretinoin (20 mg daily for 8 months) for dermal pigmentation
4. Maintenance: APC every 6 months + continued topical therapy

Dermal Hyperpigmentation (ADMH)

1. First-line: Oral isotretinoin 20 mg daily for 8 months 8
2. Best candidates: Disease duration <5 years, localized lesions, Fitzpatrick III-VI 8
3. Alternative: High-fluence laser therapy 5

Critical Pitfalls to Avoid

• Never use topical treatments alone without photoprotection - UV exposure will negate all therapeutic benefits 1
• Avoid aggressive laser procedures in darker skin types without extensive experience - high risk of worsening pigmentation 7
• Do not expect rapid results - topical therapies require 12-16 weeks minimum for visible improvement 3, 7
• Recognize dermal vs. epidermal pigmentation - dermal pigmentation responds poorly to topical agents and requires systemic or laser therapy 5
• Counsel patients that hyperpigmentation is chronic requiring long-term maintenance, not curative treatment 1

Skin of Color Considerations

For Fitzpatrick skin types IV-VI, the 2026 evidence emphasizes 3, 7:

• Stepwise approach: Start conservative with topicals + photoprotection
• Chemical peels: Use lower concentrations and test small areas first
• Cysteamine and tranexamic acid offer safer alternatives to hydroquinone
• Oral isotretinoin shows better response in darker skin types 8